Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study

Abstract

Background Lipoprotein(a) (Lp[a]) is a risk factor for cardiovascular disease and calcific aortic valve stenosis. No effective therapies to lower plasma Lp(a) concentrations exist. We have assessed the safety, pharmacokinetics, and pharmacodynamics of ISIS-APO(a)Rx, a second-generation antisense drug designed to reduce the synthesis of apolipoprotein(a) (apo[a]) in the liver. Methods In this randomised, double-blind, placebo-controlled, phase 1 study at the PAREXEL Clinical Pharmacology Research Unit (Harrow, Middlesex, UK), we screened for healthy adults aged 18-65 years, with a body-mass index less than 32·0 kg/m(2), and Lp(a) concentration of 25 nmol/L (100 mg/L) or more. Via a randomisation technique, we randomly assigned participants to receive a single subcutaneous injection of ISIS-APO(a)Rx (50 mg, 100 mg, 200 mg, or 400 mg) or placebo (3:1) in the single-dose part of the study or to receive six subcutaneous injections of ISIS-APO(a)Rx (100 mg, 200 mg, or 300 mg, for a total dose exposure of 600 mg, 1200 mg, or 1800 mg) or placebo (4:1) during a 4 week period in the multi-dose part of the study. Participants, investigators, and study staff were masked to the treatment assignment, except for the pharmacist who prepared the ISIS-APO(a)Rx or placebo. The primary efficacy endpoint was the percentage change from baseline in Lp(a) concentration at 30 days in the single-dose cohorts and at 36 days for the multi-dose cohorts. Safety and tolerability was assessed 1 week after l…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(15)61252-1

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 35 references

Cited by

See all 460

Metadata

Authors
Tsimikas, S., Viney, N. J., Hughes, S. G., Singleton, W., Graham, M. J., Baker, B. F., Burkey, J. L., Yang, Q., Marcovina, S. M., Geary, R. S., Crooke, R. M., & Witztum, J. L.
Affiliations
  • Ionis Pharmaceuticals (United States) (US)
  • University of Washington (US)
  • University of California San Diego (US)
Corresponding author
Tsimikas, Sotirios
Venue
The Lancet
Publisher
Elsevier BV
Published
2015-10
Volume
386
Issue
10002
Pages
1472-1483
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W1708837772
Cited by
460
References
35
Citations by year
2026: 11 · 2025: 31 · 2024: 22 · 2023: 32 · 2022: 37 · 2021: 48 · 2020: 44 · 2019: 53 · 2018: 42 · 2017: 48 · 2016: 78 · 2015: 13
FWCI
60.81
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Heart, Lung, and Blood Institute (P01HL088093)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords
apolipoprotein(a), lipoprotein(a), antisense therapy, cardiovascular risk, calcific aortic stenosis, pharmacokinetics, pharmacodynamics, safety and tolerability, dose escalation, complement system, healthy volunteers, lipid profile
MeSH terms
Adolescent, Adult, Aged, Apolipoproteins A, Double-Blind Method, Humans, Middle Aged, Oligonucleotides, Protein Binding, RNA, Messenger, Oligonucleotides, Antisense, Treatment Outcome, Apoprotein(a), Young Adult, Healthy Volunteers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. https://app.cochat.ai/papers/10.1016/s0140-6736(15)61252-1
The paper
Tsimikas, S., Viney, N. J., Hughes, S. G., Singleton, W., Graham, M. J., Baker, B. F., Burkey, J. L., Yang, Q., Marcovina, S. M., Geary, R. S., Crooke, R. M., & Witztum, J. L. (2015). Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. The Lancet. https://doi.org/10.1016/s0140-6736(15)61252-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.